Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis
- PMID: 15673762
- PMCID: PMC547225
- DOI: 10.1128/AAC.49.2.767-769.2005
Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis
Abstract
Echinocandins are approved for the treatment of candidal infections. In vitro they have been shown to be less potent against strains of Candida parapsilosis than against other Candida spp. This is the first case report describing the development of a secondary multidrug (echinocandin-azole)-resistant Candida strain during therapy.
References
-
- Abu-el Teen, K., M. Ghannoum, and R. J. Stretton. 1989. Effects of sub-inhibitory concentrations of antifungal agents on adherence of Candida spp. to buccal epithelial cells in vitro. Mycoses 32:551-562. - PubMed
-
- Denning, D. W. 2002. Echinocandins: a new class of antifungal. J. Antimicrob. Chemother. 49:889-891. - PubMed
-
- Diekema, D. J., S. A. Messer, R. J. Hollis, R. P. Wenzel, and M. A. Pfaller. 1997. An outbreak of Candida parapsilosis prosthetic valve endocarditis. Diagn. Microbiol. Infect. Dis. 29:147-153. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous